Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 1 9564 3324 6037 504--
Enterprise Value (EV)1 1 7473 7704 1737 1047 4207 315
P/E ratio -6,25x-12,5x-5,35x-11,5x-14,6x-45,3x
Yield ------
Capitalization / Revenue -17,3x69,2x94,9x27,7x11,2x
EV / Revenue -15,0x62,7x89,8x27,4x10,9x
EV / EBITDA -6,07x-17,7x-7,80x-12,5x-12,9x-18,4x
Price to Book 57,2x21,3x23,2x44,7x-99,7x289x
Nbr of stocks (in thousands) 63 88875 73797 358109 865--
Reference price (USD) 30,657,247,368,368,368,3
Announcement Date 02/27/202002/25/202102/28/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 -25166,679,1271670
EBITDA1 -288-213-535-567-575-397
Operating profit (EBIT)1 -288-214-536-587-515-228
Operating Margin --85,3%-806%-742%-190%-34,1%
Pre-Tax Profit (EBT)1 -305-343-746-630-559-267
Net income1 -305-345-746-627-523-180
Net margin --138%-1 121%-792%-193%-26,9%
EPS2 -4,90-4,59-8,84-5,96-4,67-1,51
Dividend per Share2 ------
Announcement Date 02/27/202002/25/202102/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 60,314,416,321,726,838,3
EBITDA1 -89,0-129-148-120-121-106
Operating profit (EBIT)1 -89,4-129-149-150-154-159
Operating Margin -148%-897%-911%-688%-576%-414%
Pre-Tax Profit (EBT)1 -148-138-155-156-165-138
Net income1 -148-139-156-157-172-138
Net margin -245%-966%-956%-722%-642%-360%
EPS2 -1,61-1,42-1,46-1,45-1,56-1,27
Dividend per Share ------
Announcement Date 02/28/202205/04/202208/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 20956243040084,2188
Leverage (Debt / EBITDA) 0,73x2,64x0,80x0,71x0,15x0,48x
Free Cash Flow1 -213-166-564-476-443-168
ROE (Net Profit / Equities) -312%-289%-370%-453%-1 211%-19,8%
Shareholders' equity1 97,611920213843,2911
ROA (Net Profit / Asset) -103%-51,1%-81,0%-66,9%-56,4%-35,1%
Assets1 296675921937928513
Book Value Per Share2 0,542,692,041,53-0,680,24
Cash Flow per Share2 -3,39-2,14-6,67-5,12-4,03-
Capex1 1,695,421,1016,13,175,34
Capex / Sales -2,16%1,66%20,4%1,17%0,80%
Announcement Date 02/27/202002/25/202102/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 7 503 800 331
Net sales (USD) 66 563 000
Number of employees 476
Sales / Employee (USD) 139 838
Free-Float 84,5%
Free-Float capitalization (USD) 6 340 055 960
Avg. Exchange 20 sessions (USD) 114 073 229
Average Daily Capital Traded 1,52%
EPS & Dividend